Study Authors
  • Piero Dalerba, MD, is a medical oncologist and an assistant professor of medicine, pathology and cell biology at Columbia University’s Herbert Irving Comprehensive Cancer Center in New York City. Dr. Dalerba directs a research laboratory whose main interest is to use modern “single-cell genomics” technologies to identify novel biomarkers of “cancer stem cells”, and to explore their potential as: 1) novel predictive biomarkers to improve treatment algorithms for cancer patients; 2) novel pharmacological targets to develop innovative anti-tumor treatments. Dr. Dalerba has a long-standing expertise in the biology and medical treatment of human colon cancer. His research contributions include: a) the observation that, in human colon carcinomas, the capacity for unlimited proliferation, also known as “cellular immortality”, is often not a constitutive trait of all malignant cells (Dalerba et al., Cancer Research, 65:2321-2329, 2005); b) the discovery of CD44 and CD166/ALCAM as robust surface markers for the ex vivo isolation of human colon “cancer stem cells” (Dalerba et al., PNAS, 100:3983-3988, 2007); c) the first use of “single-cell genomics” to dissect the cell composition of human colorectal malignancies, discover novel subtypes of human colon epithelial cells and provide formal proof of multi-lineage differentiation as an epigenetic source of intra-tumor cell heterogeneity (Dalerba et al., Nature Biotechnology, 29:1120-1127, 2011). Dr. Dalerba is the recipient of a 2016 Damon Runyon-Rachleff Innovator Award and the principal investigator on a 2012 career-development Young Investigator Award (YIA) from the National Comprehensive Cancer Network (NCCN), which supported a research project entitled: Evaluation of CDX2 as a novel predictive biomarker to guide therapeutic algorithm design in colon cancer.
    • Medical Oncology
    • Associate Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine at Stanford University
    Michael F. Clarke, MD is a Professor of Medicine in the Division of Oncology at Stanford University. He is the Karel and Avice Beekhuis Professor in Cancer Biology and the Associate Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine. His interest is in the area of Stem Cell Biology. In addition to his clinical duties in the division of Oncology, Dr. Clarke maintains a laboratory focused on two areas of research: i) the control of self-renewal of normal stem cells and diseases such as cancer and hereditary diseases; and ii) the identification and characterization of cancer stem cells. His laboratory was the first to Identify cancer stem cells in solid tumors including breast and colon cancer In addition, he is actively seeking new treatment targets that can lead to improved cancer treatments.
    • Biostatistics
    • Colorectal Caner
    • Clinical Trials
    Biostatistician at University of Pittsburgh and NRG Oncology
    Biostatistician at University of Pittsburgh and NRG Oncology
    • Research Associate Professor of Biostatistics, Director of the Division of Biostatistics and Science for the Pittsburgh Office of the NRG Oncology Statistics and Data Management Center at Graduate School of Public Health at the University of Pittsburgh
    Greg Yothers, PhD is a Research Associate Professor of Biostatistics at the Graduate School of Public Health of the University of Pittsburgh and Director of the Division of Biostatistics and Science for the Pittsburgh office of the NRG Oncology Statistics and Data Management Center. Dr. Yothers develops, oversees the conduct of, and analyzes clinical trials in the areas of breast, genitourinary, and colorectal cancers in his role with NRG Oncology and provides administrative support for the statistics group. He is a member of the National Cancer Institute’s Gastrointestinal Cancers Steering Committee and the American Society for Clinical Oncology. His methodological work has focused on identifying a subset of a clinical trial or population where a treatment is effective and on finding early surrogate endpoints for overall survival to expedite clinical research. His Neoadjuvant Rectal cancer (NAR) score has been demonstrated to be superior to pathologic complete response as a surrogate endpoint for survival. Dr. Yothers’ abstract “The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer” won an American Society for Clinical Oncology 2011 Annual Meeting “Best of ASCO” award.
    • Assistant Professor at University of California San Diego
    Debashis Sahoo received his MS and PhD in Electrical Engineering at Stanford University, and BTech in Computer Science and Engineering at IIT-Kharagpur. He is currently working as an assistant professor in the division of Genome Information Sciences within the Department of Pediatrics at University of California, San Diego, CA USA (UCSD). He also hold an affiliated faculty position in the Department of Computer Science and Engineering, and in the Bioinformatics and Systems Biology graduate program at UCSD.​ Before joining UCSD as a faculty member in 2014, he was an Instructor of Pathology and a Siebel research fellow at the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University. He has several publications in the area of computational biology and formal verification. He finished his doctoral work under the NCI-funded Integrative Cancer Biology Program at Stanford with his advisor Prof. David Dill and co-advisor Prof. Sylvia Plevritis. His postdoctoral advisee includes Prof. Joe Lipsick, Prof. Matt van de Rijn, Prof. Irv Weissman, and Prof. Michael Clarke. He has used Boolean logic to understand the process of differentiation in normal and cancer tissues. His current research interests include the analysis of high throughput biological datasets, systems biology, allergy, infection and heart diseases. He has published over 50 manuscripts on his research in the area of computational biology and formal verification, and he is a co-inventor on five issued patents.